A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
2,369actual
Sites
116
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-26 | actual | When the study began enrolling |
| Primary completion | 2025-12-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-31 | actual | The whole study's end, after follow-up |
| First posted | 2020-09-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Rheumatoid Arthritis (RA)
- Atopic Dermatitis (AD)
- Ankylosing Spondylitis (AS)
- Psoriatic Arthritis (PsA)
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants With Adverse Events
measured Up to approximately 6 years
Percentage of Participants Achieving Responder Status Based on Disease Activity Score 28 Joints (DAS28) (Rheumatoid Arthritis Participants Only)
measured Up to 24 weeks
Percentage of Participants Achieving Responder Status Based on Eczema Area and Severity Index (EASI) (Atopic Dermatitis Participants Only)
measured Up to 16 weeks
Percentage of Participants Achieving Responder Status Based on Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (Ankylosing Spondylitis Participants Only)
measured Up to 12 weeks
Percentage of Participants Achieving the Responder status Based on Active Joint Count (Psoriatic Arthritis Participants Only)
measured Up to 12 weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed